NYSEAMERICAN:SYN Synthetic Biologics (SYN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Synthetic Biologics Stock (NYSEAMERICAN:SYN) Get Synthetic Biologics alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume57,700 shsAverage Volume197,338 shsMarket Capitalization$16.16 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Synthetic Biologics, Inc. is a clinical‐stage biopharmaceutical company headquartered in Rockville, Maryland, focused on developing novel therapies to prevent and treat serious bacterial infections by preserving the integrity of the gut microbiome. The company’s research platform leverages enzyme and microbiome modulation technologies to counteract the unintended consequences of antibiotic therapies, aiming to reduce the incidence of Clostridioides difficile infection and other antibiotic‐associated complications. The company’s lead product candidate, ribaxamase (SYN-004), is an orally administered beta‐lactamase enzyme designed to degrade certain intravenous beta‐lactam antibiotics in the gastrointestinal tract, thereby protecting the gut from antibiotic‐induced dysbiosis. Ribaxamase has been evaluated in multiple clinical trials, including studies in patients undergoing treatment for serious infections such as pneumonia. Synthetic Biologics has also been advancing additional pipeline programs that explore microbiome‐based approaches for gastrointestinal and metabolic disorders. Synthetic Biologics collaborates with pharmaceutical partners to facilitate global development and commercialization, having secured agreements to support late‐stage studies and future market access. The company is led by President and Chief Executive Officer William H. Martin, under the guidance of an experienced board with deep expertise in biopharmaceutical research and development. Synthetic Biologics is committed to innovating solutions that address critical unmet needs in infectious disease and gastrointestinal health.AI Generated. May Contain Errors. Read More Receive SYN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Synthetic Biologics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SYN Stock News HeadlinesStudy Shows NanoFuse(R) Superiority: Why Bioactive Glass-DBM Composites Outperform DBM and Bioactive Glass AloneJanuary 26, 2026 | marketwatch.comMTF Biologics and Kolosis BIO Launch New Solution for Orthopedic and Spinal Surgeries: Summit Matrix™January 15, 2026 | uk.finance.yahoo.comConfirm Your Name Before the Letter Goes OutAmericans who believe in real retirement protection are adding their names to a statement going out to Washington and Wall Street. It's a message that people are fed up with inflation and the erosion of their savings. President Trump took a stand on protecting American wealth. Now you can add your voice while also learning how to move part of your IRA or 401(k) into physical gold and silver, tax and penalty free.July 17 at 1:00 AM | American Alternative (Ad)MTF Biologics and Kolosis BIO Launch New Solution for Orthopedic and Spinal Surgeries: Summit Matrix(TM)January 15, 2026 | marketwatch.comAurora Spine Launches New Biologics PortfolioOctober 28, 2025 | markets.businessinsider.comWound Care Biologics Market Size Worth USD 11.22 Billion by 2034October 27, 2025 | finance.yahoo.comActive Pharmaceutical Ingredients (API) Market worth $198.39 billion by 2030 with 6.6% CAGR | MarketsandMarkets™October 15, 2025 | finance.yahoo.comProtein Expression Market to Hit USD 6.60 Billion by 2032 on Rising Biologics and Personalized Medicine Demand | S&S InsiderSeptember 26, 2025 | finance.yahoo.comSee More Headlines SYN Stock Analysis - Frequently Asked Questions How were Synthetic Biologics' earnings last quarter? Synthetic Biologics, Inc. (NYSEAMERICAN:SYN) posted its quarterly earnings results on Tuesday, November, 2nd. The company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.30) by $0.10. When did Synthetic Biologics' stock split? Shares of Synthetic Biologics reverse split before market open on Monday, July 25th 2022.The 1-10 reverse split was announced on Monday, July 25th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Synthetic Biologics? Shares of SYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Synthetic Biologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Synthetic Biologics investors own include Tonix Pharmaceuticals (TNXP), Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Palatin Technologies (PTN) and Meta Platforms (META). Company Calendar Last Earnings11/02/2021Today7/17/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNYSEAMERICAN:SYN CIK894158 Webwww.syntheticbiologics.com Phone(301) 417-4364Fax301-417-4367Employees16Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$14.27 million Net MarginsN/A Pretax MarginN/A Return on Equity-26.14% Return on Assets-22.74% Debt Debt-to-Equity RatioN/A Current Ratio4.14 Quick Ratio4.14 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.95 per share Price / BookN/AMiscellaneous Outstanding Shares15,844,000Free Float15,503,000Market Cap$16.16 million OptionableNot Optionable Beta1.38 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NYSEAMERICAN:SYN) was last updated on 7/17/2026 by MarketBeat.com Staff. From Our PartnersLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredElon’s new "tollbooth"The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synthetic Biologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synthetic Biologics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SYN Stock Alerts